Quarterly report · Q2
2413.TEDINET S100PJMD
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥112.6bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥55.6bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥97.6bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥51.2bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥36.3bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥17.6bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥61.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥37.3bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥38.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥18.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥62.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥37.5bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥24.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥11.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥40.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥25.0bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥26.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥12.5bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥42.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥25.8bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥377.7bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥346.0bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥308.4bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥86.4bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥82.0bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥291.3bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥264.0bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥237.7bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥207.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥284.5bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥257.8bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥231.4bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥100.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥104.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥87.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥89.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥25.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥18.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥18.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥14.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥13.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥35.44 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥17.58 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥60.09 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥36.86 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥35.42 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥17.57 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥60.04 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥36.83 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.3% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.0% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 107
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥2.8bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥1.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥2.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥701m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥231m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥445m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥179m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥634m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.7bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥347m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥185m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥42.5bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥22.3bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥40.9bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥21.6bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥664m |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥18.8bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥10.0bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥15.3bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥15.3bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥18.8bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥8.6bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥18.5bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥8.6bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥304m |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥865m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥113.9bn |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥55.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥111.2bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥54.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥1.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥36.9bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥17.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥1.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥2.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥1.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥520m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥376m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥8.2bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥7.8bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥364m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥338m |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E05425-000Career Solutionreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥979m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥9.6bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥483m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥288m |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E05425-000Evidence Solutionreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥38.4bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥19.5bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥37.1bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥18.8bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥622m |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥16.7bn |
| jpcrp040300-q2r_E05425-000Medical Platformreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥8.5bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥12m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥1m |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥38.1bn |
| jpcrp040300-q2r_E05425-000Overseasreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥25.2bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥17.5bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥12.2bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥17.2bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥11.9bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥238m |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥238m |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E05425-000Site Solutionreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥2.0bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥98.6bn |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥52.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥96.2bn |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥50.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2.4bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥1.5bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥62.9bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥37.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 824
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration | 2977000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 40923000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 13656000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 7921000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 18475000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 30185000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 111160000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 1457000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 112616000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 1614000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 347000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 445000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 304000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 4000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 2715000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 49000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -2764000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration | － | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 42537000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 14003000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 8366000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 18779000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 30189000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 113874000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 1506000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -2764000000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 112616000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 18762000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 4248000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 3464000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 2312000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 8118000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 36905000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 90000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -701000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 36293000000 | JPY |
| Finance income and expenses net IFRS | CurrentYTDDuration | 1773000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 38067000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 1317000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000EvidenceSolutionReportableSegmentMember | 270000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000CareerSolutionReportableSegmentMember | 48000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000SiteSolutionReportableSegmentMember | 575000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OverseasReportableSegmentMember | 1170000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReportableSegmentsMember | 3381000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000OtherEmergingBusinessMember | 109000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration | 3490000000 | JPY |
| Reversal of impairment losses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05425-000MedicalPlatformReportableSegmentMember | 820000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |